It has been recognised for over two decades that breast cancers associated with BRCA1 pathogenic variants are predominantly triple receptor (ER, PR and HER2) negative, high grade invasive ductal carcinomas with high numbers of tumour infiltrating lymphocytes (TILs) 6, 7, 8, 9, 10. This evidence concerns the gene ERBB2 and breast carcinoma.